Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Martin

Showing results (281-290 of 361) with videos related to

Pageof 37
Sort By:
Plos One|March 17, 2021
Wear patterns and dental functioning in an Early Cretaceous stegosaur from Yakutia, Eastern RussiaPavel P Skutschas, Vera A Gvozdkova, Alexander O Averianov, et al.
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
International Journal of Hematology|May 16, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysisKihyun Kim, Chang-Ki Min, Youngil Koh, et al.
The Journal of Allergy and Clinical Immunology|May 16, 2013
T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell deathHye Young Kim, Ya-Jen Chang, Ya-Ting Chuang, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2019
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study ResultsMatthew J Wieduwilt, Nela Pawlowska, Scott Thomas, et al.
Plos One|September 1, 2020
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurementsMaria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup AnalysisYawara Kawano, Kihyun Kim, Chang Ki Min, et al.
Blood|July 5, 2003
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 yearsRaymond Wong, Sergio A Giralt, Thomas Martin, et al.
Pageof 37

Showing results (281-290 of 361) with videos related to

Sort By:
Pageof 37
Plos One|March 17, 2021
Wear patterns and dental functioning in an Early Cretaceous stegosaur from Yakutia, Eastern RussiaPavel P Skutschas, Vera A Gvozdkova, Alexander O Averianov, et al.
Blood|April 8, 2004
Tumor necrosis factor-alpha blockade for the treatment of acute GVHDDaniel Couriel, Rima Saliba, Krystal Hicks, et al.
International Journal of Hematology|May 16, 2022
Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysisKihyun Kim, Chang-Ki Min, Youngil Koh, et al.
The Journal of Allergy and Clinical Immunology|May 16, 2013
T-cell immunoglobulin and mucin domain 1 deficiency eliminates airway hyperreactivity triggered by the recognition of airway cell deathHye Young Kim, Ya-Jen Chang, Ya-Ting Chuang, et al.
Annals of Hematology|August 9, 2022
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomesXavier Leleu, Thomas Martin, Katja Weisel, et al.
Blood Advances|May 20, 2022
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myelomaThomas Martin, Joseph Mikhael, Roman Hajek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2019
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study ResultsMatthew J Wieduwilt, Nela Pawlowska, Scott Thomas, et al.
Plos One|September 1, 2020
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurementsMaria-Teresa Cedena, Estela Martin-Clavero, Sandy Wong, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2023
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup AnalysisYawara Kawano, Kihyun Kim, Chang Ki Min, et al.
Blood|July 5, 2003
Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 yearsRaymond Wong, Sergio A Giralt, Thomas Martin, et al.
Pageof 37